Results 31 to 40 of about 273,925 (284)

Annexin A3, a Calcium-Dependent Phospholipid-Binding Protein: Implication in Cancer

Frontiers in Molecular Biosciences, 2021
Annexin A3 (ANXA3), also known as lipocortin III and placental anticoagulant protein III, has been reported to be dysregulated in tumor tissues and cancer cell lines, and harbors pronounced diagnostic and prognostic value for certain malignancies, such ...
Liu Yang, Pingan Lu, Xiaohui Yang, Kaiguo Li, Song Qu   +4 more
doaj   +1 more source

Strategic therapeutic approaches to overcome emerging dual SRC/ABL kinase inhibitors resistances in chronic phase Ph positive chronic myeloid leukemia

Asian Journal of Medical Sciences, 2014
Chronic myeloid leukemia (CML) is a haematopoietic neoplasm with clinically distinct phases and BCR⁄ABL1 oncogene. Imatinib mesylate, a potent inhibitor of BCR-ABL was highly effective in CML but later in-vitro derived cell line with resistance namely ...
Rajat Rana
doaj   +1 more source

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

Frontiers in Pharmacology, 2021
Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM.
Omar S. Al-Odat, Omar S. Al-Odat, Max von Suskil, Max von Suskil, Robert J. Chitren, Robert J. Chitren, Weam O. Elbezanti, Weam O. Elbezanti, Sandeep K. Srivastava, Tulin Budak-Alpddogan, Subash C. Jonnalagadda, Bharat B. Aggarwal, Manoj Pandey   +12 more
doaj   +1 more source

MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells

, 2021
Introduction: Dysregulation of the mechanistic target of rapamycin complex 1 (mTORC1)-dependent pathways in pancreatic neuroendocrine neoplasms (PanNENs) underlies the introduction of the mTORC1 inhibitor everolimus as treatment of advanced progressive ...
Sette, Claudio, Arcidiacono, Paolo Giorgio, Rinzivillo, Maria, Capone, Alessia, Pilozzi, Emanuela, Partelli, Stefano, Capurso, Gabriele, Terracciano, Francesca, Montori, Andrea, Panzuto, Francesco   +9 more
core   +1 more source

Essential procedures of single-cell RNA sequencing in multiple myeloma and its translational value

Blood Science, 2023
Multiple myeloma (MM) is a malignant neoplasm characterized by clonal proliferation of abnormal plasma cells. In many countries, it ranks as the second most prevalent malignant neoplasm of the hematopoietic system.
Jun Du, Xiao-Ran Gu, Xiao-Xiao Yu, Yang-Jia Cao, Jian Hou   +4 more
doaj   +1 more source

DataSheet1_Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1.docx

, 2022
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, driven by the BCR-ABL1 fusion oncoprotein. The discovery of orthosteric BCR-ABL1 tyrosine kinase inhibitors (TKIs) targeting its active ATP-binding pocket, such as first-generation Imatinib
Shaoyong Lu (280642), Kui Du (3488084), Mingsheng Zhu (286113), Yuanhao Wang (1534042), Liping Deng (756374), Mingzi Li (9539444), Duan Ni (5565305), Hui Shi (278337), Chen Cai (529654), Hao Zhang (15339)   +9 more
core   +1 more source

In silico drug repurposing and lipid bilayer molecular dynamics puzzled out potential breast cancer resistance protein (BCRP/ABCG2) inhibitors

, 2022
Multidrug resistance (MDR) is a fundamental reason for the fiasco of carcinoma chemotherapy. A wide variety of anticarcinoma drugs are expelled from neoplasm cells through the ATP-binding cassette (ABC) transporter superfamily, rendering the neoplasm ...
Nahlah Makki Almansour (12966164), Ekram Ismail Fagiree (13818332), Alaa H. M. Abdelrahman (9269422), Mahmoud A. A. Ibrahim (9258480)   +3 more
core   +1 more source

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1

Frontiers in Pharmacology, 2022
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, driven by the BCR-ABL1 fusion oncoprotein. The discovery of orthosteric BCR-ABL1 tyrosine kinase inhibitors (TKIs) targeting its active ATP-binding pocket, such as first-generation Imatinib
Hao Zhang, Hao Zhang, Mingsheng Zhu, Mingzi Li, Duan Ni, Yuanhao Wang, Liping Deng, Kui Du, Shaoyong Lu, Hui Shi, Chen Cai   +10 more
doaj   +1 more source

Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates [PDF]

BioImpacts, 2019
Despite rapid advances in diagnostic and treatment approaches, the overall survival rate of cancer has not been improved. Colorectal cancer (CRC) is recognized as the third leading cause of neoplasm-related deaths worldwide, in large part due to its ...
Mostafa Akbarzadeh Khiavi, Azam Safary, Mohammad Hossein Somi   +2 more
doaj   +1 more source

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

, 2011
The KRAS mutation is not responsible for all cases of resistance to anti-epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new predictive and prognostic factors are actively being ...
Tonia Cenci, Ferrara, Anna Maria, Mariantonietta Di Salvatore, Armando Orlandi, Cassano, Alessandra, Alessandro Inno, Larocca, Luigi Maria, Barone, Carlo Antonio, Orlandi, Armando, Strippoli, Antonia, Alessandra Cassano, Maurizio Martini, Carlo Barone, Di Salvatore, Mariantonietta, Luigi Maria Larocca, Anna Maria Ferrara, Antonia Strippoli, Cinzia Bagalà, Inno, Alessandro, Martini, Maurizio, Bagala', Cinzia, Cenci, Tonia   +21 more
core   +1 more source